Clinical Trials Search
Clinical Trial 19365
Cancer Type: Sarcoma
Study Type: Treatment
NCT#: NCT03600649
Phase: Phase I
Prinicipal Investigator: Damon Reed
Study Title
Phase I Trial of the LSD1 inhibitor SP-2577 in Patients with Relapsed or Refractory Ewing Sarcoma
Summary
The purpose of this study is to evaluate the safety and tolerability of SP-2577 in patients with relapsed or refractory Ewing sarcoma.
Objective
Primary Objective: To evaluate the safety and tolerability of SP-2577 in patients with relapsed or refractory Ewing sarcoma. Secondary Objectives: To determine the MTD of SP-2577 in patients with refractory or recurrent Ewing sarcoma. To characterize pharmacokinetics of SP-2577. To evaluate the anti-tumor activity of SP-2577 in patients with refractory or recurrent Ewing sarcoma. Exploratory Objective: Explore the use of circulating tumor cells (CTC), cell-free DNA (cfDNA) and Hemoglobin F as pharmacodynamic markers of disease burden, drug effect, and tumor response.
Therapies
Medications
SP-2577 ()
If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.